menu
    • menu
    [{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ARC101","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Third Arc Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Third Arc Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Arc Bio \/ Inapplicable"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Third Arc Bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Third Arc Bio \/ Vida Ventures LLC","highestDevelopmentStatusID":"3","companyTruncated":"Third Arc Bio \/ Vida Ventures LLC"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Third Arc Bio

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Third Arc Bio

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Third Arc Bio

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARC101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Third Arc Bio Doses First Patient in Phase 1 Trial of ARC101 for CLDN6+ Cancers

                            Details : ARC101, a potential best-in-class T cell engager targeting Claudin 6 (CLDN6). It is being evaluated for the treatment of locally advanced or metastatic solid tumors expressing CLDN6.

                            Product Name : ARC101

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : ARC101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Third Arc Bio

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Third Arc Bio

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Vida Ventures LLC

                            Deal Size : $165.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            J&J vets burst into biotech with $165M Third Arc series A

                            Details : The financing will advance the company in developing multifunctional antibodies & to evaluate through clinical studies to address significant unmet needs in oncology and autoimmunity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Vida Ventures LLC

                            Deal Size : $165.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth